{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:54:00Z","timestamp":1768438440687,"version":"3.49.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPPS"],"published-print":{"date-parts":[[2020,12,31]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Infectious diseases caused by viruses have become a serious public health issue in the recent\npast, including the current pandemic situation of COVID-19. Enveloped viruses are most commonly\nknown to cause emerging and recurring infectious diseases. Viral and cell membrane fusion is the major\nkey event in the case of enveloped viruses that is required for their entry into the cell. Viral fusion\nproteins play an important role in the fusion process and in infection establishment. Because of this,\nthe fusion process targeting antivirals become an interest to fight against viral diseases caused by the\nenveloped virus. Lower respiratory tract infections casing viruses like influenza, respiratory syncytial\nvirus (RSV), and severe acute respiratory syndrome coronavirus (SARS-CoV) are examples of such\nenveloped viruses that are at the top in public health issues. Here, we summarized the viral fusion protein\ntargeted antiviral peptides along with their mechanism and specific design to combat the viral\nfusion process. The pandemic COVID-19, severe respiratory syndrome disease is an outbreak worldwide.\nThere are no definitive drugs yet, but few are in on-going trials. Here, an approach of fragmentbased\ndrug design (FBDD) methodology is used to identify the broad spectrum agent target to the conserved\nregion of fusion protein of SARS CoV-2. Three dipeptides (DL, LQ and ID) were chosen from\nthe library and designed by the systematic combination along with their possible modifications of\namino acids to the target sites. Designed peptides were docked with targeted fusion protein after energy\nminimization. Results show strong and significant binding affinity (DL = -60.1 kcal\/mol; LQ = -\n62.8 kcal\/mol; ID= -71.5 kcal\/mol) during interaction. Anyone of the active peptides from the developed\nlibraries may help to block the target sites competitively to successfully control COVID-19.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389203721666200908164641","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T11:55:15Z","timestamp":1599652515000},"page":"938-947","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Fusion Protein Targeted Antiviral Peptides: Fragment-Based Drug Design (FBDD) Guided Rational Design of Dipeptides Against SARS-CoV-2"],"prefix":"10.2174","volume":"21","author":[{"given":"Sounik","family":"Manna","sequence":"first","affiliation":[{"name":"Central Research Facility, Indian Institute of Technology Kharagpur, Kharagpur 721302, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinath","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Central Research Facility, Indian Institute of Technology Kharagpur, Kharagpur 721302, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyush","family":"Baindara","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, University of Missouri, Columbia 65212, MO, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santi M.","family":"Mandal","sequence":"additional","affiliation":[{"name":"Central Research Facility, Indian Institute of Technology Kharagpur, Kharagpur 721302, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Protein &amp; Peptide Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185751","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185751\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T06:25:26Z","timestamp":1609482326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185751\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,12,31]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389203721666200908164641","relation":{},"ISSN":["1389-2037"],"issn-type":[{"value":"1389-2037","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}